

Kenneth C Kalunian

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7305608/kenneth-c-kalunian-publications-by-citations.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

64 papers	4,449 citations	24 h-index	66 g-index
94 ext. papers	5,785 ext. citations	6.6 avg, IF	4.87 L-index

#	Paper	IF	Citations
64	Combined oral contraceptives in women with systemic lupus erythematosus. <i>New England Journal of Medicine</i> , 2005 , 353, 2550-8	59.2	742
63	Anifrolumab, an Anti-Interferon- γ Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2017 , 69, 376-386	9.5	430
62	The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. <i>Annals of Internal Medicine</i> , 2005 , 142, 953-62	8.2	415
61	Sifalimumab, an anti-interferon- γ monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1909-1916	2.4	309
60	The immune cell landscape in kidneys of patients with lupus nephritis. <i>Nature Immunology</i> , 2019 , 20, 902-914	19.1	254
59	Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1706-13	2.4	250
58	Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. <i>Lancet, The</i> , 2018 , 392, 222-231	40	243
57	A Phase II study of the efficacy and safety of rontalizumab (rhuMAB interferon- γ) in patients with systemic lupus erythematosus (ROSE). <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 196-202	2.4	230
56	The frequency and outcome of lupus nephritis: results from an international inception cohort study. <i>Rheumatology</i> , 2016 , 55, 252-62	3.9	210
55	Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 183-90	2.4	205
54	Clinical significance of a single test for anti-cardiolipin antibodies in patients with systemic lupus erythematosus. <i>American Journal of Medicine</i> , 1988 , 85, 602-8	2.4	139
53	Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials. <i>Arthritis and Rheumatology</i> , 2017 , 69, 362-375	9.5	125
52	Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. <i>Lancet Rheumatology, The</i> , 2019 , 1, e208-e219	14.2	117
51	Validation of American College of Rheumatology classification criteria for knee osteoarthritis using arthroscopically defined cartilage damage scores. <i>Seminars in Arthritis and Rheumatism</i> , 2005 , 35, 197-201	5.3	77
50	Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 883-889	2.4	60
49	Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements. <i>Lupus Science and Medicine</i> , 2014 , 1, e000056	4.6	54
48	Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1530-6	2.4	51

47	CXCL13: a novel biomarker of B-cell return following rituximab treatment and synovitis in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2011 , 50, 603-10	3.9	51
46	Elevated autoantibody content in rheumatoid arthritis synovia with lymphoid aggregates and the effect of rituximab. <i>Arthritis Research and Therapy</i> , 2008 , 10, R105	5.7	50
45	Systemic lupus international collaborating clinics renal activity/response exercise: development of a renal activity score and renal response index. <i>Arthritis and Rheumatism</i> , 2008 , 58, 1784-8		49
44	Antinuclear Antibody-Negative Systemic Lupus Erythematosus in an International Inception Cohort. <i>Arthritis Care and Research</i> , 2019 , 71, 893-902	4.7	46
43	Work disability, lost productivity and associated risk factors in patients diagnosed with systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , 2015 , 2, e000058	4.6	37
42	Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2019 , 71, 281-289	9.5	31
41	New directions in the treatment of systemic lupus erythematosus. <i>Current Medical Research and Opinion</i> , 2009 , 25, 1501-14	2.5	26
40	Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort. <i>Rheumatology</i> , 2018 , 57, 677-687	3.9	20
39	Idiotypic spreading promotes the production of pathogenic autoantibodies. <i>Journal of Autoimmunity</i> , 1988 , 1, 47-61	15.5	19
38	Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 356-362	2.4	18
37	Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2020 , 72, 67-77	9.5	18
36	Reduction in erythrocyte-bound complement activation products and titres of anti-C1q antibodies associate with clinical improvement in systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , 2016 , 3, e000165	4.6	16
35	Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019 , 71, 1297-1307	9.5	15
34	Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , 2020 , 106, 102340	15.5	15
33	Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE. <i>Lupus Science and Medicine</i> , 2018 , 5, e000263	4.6	14
32	Arthroscopic synovectomy by rheumatologists: time for a new look. <i>Arthritis and Rheumatism</i> , 1989 , 32, 109-11		13
31	Idiotypic characteristics of immunoglobulins associated with human systemic lupus erythematosus. Association of high serum levels of IgG2 with nephritis but not with HLA class II genes predisposing to nephritis. <i>Arthritis and Rheumatism</i> , 1990 , 33, 978-84		12
30	Preferential recognition of a fragment species of osteoarthritic synovial fluid fibronectin by antibodies to the alternatively spliced EIIIA segment. <i>Arthritis and Rheumatism</i> , 2001 , 44, 2572-85		10

29	Immunosuppressant use and hospitalisations in adult patients with systemic lupus erythematosus admitted to a tertiary academic medical centre. <i>Lupus Science and Medicine</i> , 2018 , 5, e000249	4.6	9
28	Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort. <i>Arthritis and Rheumatology</i> , 2020 , 72, 1734-1740	9.5	7
27	Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials.. <i>Annals of the Rheumatic Diseases</i> , 2022 ,	2.4	6
26	Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. <i>Rheumatology</i> , 2019 , 58, 1259-1267	3.9	5
25	Multi-cell type gene coexpression network analysis reveals coordinated interferon response and cross-cell type correlations in systemic lupus erythematosus. <i>Genome Research</i> , 2021 , 31, 659-676	9.7	5
24	Prevalence of Crystals in Knee Osteoarthritis: Experience From Patients Undergoing Arthroscopic Procedures. <i>Journal of Clinical Rheumatology</i> , 2019 , 25, 51-53	1.1	5
23	Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies.. <i>Lupus Science and Medicine</i> , 2021 , 8,	4.6	5
22	Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	4
21	Why Not Wash Out the Osteoarthritic Knee?. <i>Journal of Clinical Rheumatology</i> , 2021 , 27, 43-45	1.1	3
20	Arthroscopy in rheumatology: where have we been? Where might we go?. <i>Rheumatology</i> , 2021 , 60, 518-528	3.9	3
19	Evaluating duration of response to treatment in systemic lupus erythematosus clinical trials. <i>Lupus Science and Medicine</i> , 2018 , 5, e000266	4.6	3
18	Prediction of hospitalizations in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI). <i>Arthritis Care and Research</i> , 2020 ,	4.7	2
17	The immune cell landscape in kidneys of lupus nephritis patients		2
16	Creatinine Fluctuation in Patients With Lupus Nephritis: Considerations for Clinical Trial Endpoints. <i>Kidney International Reports</i> , 2020 , 5, 1302-1305	4.1	2
15	Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception Cohort. <i>Arthritis and Rheumatology</i> , 2021 , 73, 2293-2302	9.5	2
14	199 Baricitinib in patients with systemic lupus erythematosus: results from a phase 2, randomized, double-blind, placebo-controlled study 2019 ,		2
13	Will rheumatologists ever pick up the arthroscope again?. <i>International Journal of Rheumatic Diseases</i> , 2021 , 24, 1235-1246	2.3	2
12	Idiotypic selection is an immunoregulatory mechanism which contributes to the pathogenesis of systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , 1988 , 1, 673-681	15.5	1

11	Integrative transcriptomic analysis of SLE reveals IFN-driven cross-talk between immune cells		1
10	The ALPHA Project: Establishing consensus and prioritisation of global community recommendations to address major challenges in lupus diagnosis, care, treatment and research. <i>Lupus Science and Medicine</i> , 2021 , 8,	4.6	1
9	Clinical meaningfulness of a British Isles Lupus Assessment Group-based Composite Lupus Assessment response in terms of patient-reported outcomes in moderate to severe systemic lupus erythematosus: a post-hoc analysis of the phase 3 TULIP-1 and TULIP-2 trials of anifrolumab. <i>Lancet Rheumatology, The</i> , 2022 , 4, e198-e207	14.2	1
8	Arthroscopy in Rheumatology. <i>Arthroscopy - Journal of Arthroscopic and Related Surgery</i> , 2021 , 37, 1364-1365	3.65	0
7	Monitoring Disease Activity 2011 , 697-705		
6	Design of Clinical Trials for SLE 2011 , 719-726		
5	SLE-Associated Tests 2005 , 210-220		
4	Definition, Classification, Activity and Damage Indices in Systemic Lupus Erythematosus 2019 , 328-338		
3	Idiotypic Selection is an Immunoregulatory Mechanism which Contributes to the Pathogenesis of Systemic Lupus Erythematosus 1989 , 177-185		
2	Monitoring disease activity 2021 , 407-422		
1	Regarding Arthroscopy: Can Orthopedists and Rheumatologists Be Friends?. <i>Journal of Clinical Rheumatology</i> , 2022 , 28, 177-181	1.1	